Innovative Combination TherapiesRecent preclinical studies have shown that when buntanetap is combined with a GLP-1 agonist or PDE5 inhibitors, cognitive function in Alzheimer’s mouse models improves to levels beyond those observed in healthy controls.
Intellectual Property StrengtheningThe company has filed a new composition of matter patent for a novel crystal form of buntanetap, which offers improved properties such as enhanced solubility and stability, further strengthening its IP portfolio by extending the patent protection by an additional 20 years.
Regulatory ApprovalFDA granted clearance to Annovis Bio to proceed with pivotal Phase 3 studies of its lead candidate buntanetap.